Neurolixis Inc. offers a warm welcome to Fabienne Herbrecht, as Director of Clinical Development.
Dr. Herbrecht has gained extensive experience of drug development at a clinical level in several large and medium-sized pharmaceutical companies where she managed development, regulatory and clinical programs on drug candidates. Her expertise will be valuable as Neurolixis moves forward with development of its drug pipeline, notably as concerns targeting Parkinson's disease with the Phase 2A clinical candidate, NLX-112.

See more information concerning Neurolixis' management team here.